Prospective Grant of Exclusive Patent License: Radiotherapeutics for Nasopharyngeal Cancer, 62866-62867 [2022-22476]
Download as PDF
<![CDATA[
62866
Federal Register / Vol. 87, No. 199 / Monday, October 17, 2022 / Notices
lotter on DSK11XQN23PROD with NOTICES1
Contact Person: Kaushiki Mazumdar,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 594–1427, kaushiki.mazumdar@
nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Topics in
Bacterial Pathogenesis.
Date: November 9–10, 2022.
Time: 10 a.m. to 7 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Diana Maria Ortiz-Garcia,
Ph.D., Scientific Review Officer, The Center
for Scientific Review, The National Institutes
of Health, 6701 Rockledge Drive, Bethesda,
MD 20892, 301–594–5614, diana.ortizgarcia@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA–NS–
22–034: HEAL Initiative.
Date: November 9, 2022.
Time: 11 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Roger Janz, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 402–8515, janzr2@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Motivated Behavior, Alcohol and
Neurotoxicology.
Date: November 9, 2022.
Time: 11 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Kirk Thompson, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5184,
MSC 7844, Bethesda, MD 20892, 301–435–
1242, kgt@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: October 7, 2022.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–22417 Filed 10–14–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent
License: Radiotherapeutics for
Nasopharyngeal Cancer
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Heart, Lung and
Blood Institute (NHLBI), National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
patent license to Molecular Targeting
Technologies, Inc. (MTTI); a Delaware
corporation, with its principle place of
business in West Chester, Pennsylvania,
to practice the inventions embodied in
the issued patents and patent
applications listed in the
Supplementary Information section of
this notice.
SUMMARY:
Only written comments and/or
applications for a license which are
received by the NHLBI Office of
Technology Transfer and Development
November 1, 2022 will be considered.
DATES:
Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
exclusive patent license should be
directed to: Michael Davis, JD, Ph.D.,
Deputy Director, NHLBI OTTAD, 31
Center Drive Room 4A29, MSC2479,
Bethesda, MD 20892–2479, phone
number 301–451–9032, or
michael.davis4@nih.gov.
ADDRESSES:
The
following and all continuing U.S. and
foreign patents/patent applications
thereof are the intellectual properties to
be licensed under the prospective
agreement to MTTI:
SUPPLEMENTARY INFORMATION:
NIH Ref No.
Patent No. or patent
application No.
Issue date
Filing date
Title
E–150–2016–0–US–01
62/333,427 .................
....................................
May 9, 2019 ..............
E–150–2016–0–PCT–
02.
PCT/US2017/031696
....................................
May 9, 2017 ..............
E–150–2016–0–CN–
03.
201780029003X .........
....................................
November 9, 2018 .....
E–150–2016–0–EP–04
3455206 .....................
November 4, 2020 .....
May 9, 2017 ..............
E–150–2016–0–JP–05
2018–558662 .............
TBD (Allowed) ...........
May 9, 2017 ..............
E–150–2016–0–US–06
10,696,637 .................
June 30, 2020 ...........
May 9, 2017 ..............
E–150–2016–0–SG–
07.
11201809982R ..........
November 8, 2021 .....
May 9, 2017 ..............
E–150–2016–0–CH–
08.
3455206 .....................
November 4, 2020 .....
May 9, 2017 ..............
E–150–2016–0–DE–09
3455206 .....................
(Certificate No.
602017027023.7).
3455206 .....................
November 4, 2020 .....
May 9, 2017 ..............
November 4, 2020 ....
May 9, 2017 ..............
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and
Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and
Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and
Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and
Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and
Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and
Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and
Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and
Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and
Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and
Imaging Agents.
E–150–2016–0–FR–10
VerDate Sep<11>2014
17:35 Oct 14, 2022
Jkt 259001
PO 00000
Frm 00085
Fmt 4703
Sfmt 4703
E:\FR\FM\17OCN1.SGM
17OCN1
62867
Federal Register / Vol. 87, No. 199 / Monday, October 17, 2022 / Notices
Patent No. or patent
application No.
Issue date
Filing date
Title
E–150–2016–0–GB–
11.
3455206 .....................
November 4, 2020 ....
May 9, 2017 ..............
E–150–2016–0–IE–12
3455206 .....................
November 4, 2020 ....
May 9, 2017 ..............
E–150–2016–0–IT–13
3455206 .....................
November 4, 2020 .....
May 9, 2017 ..............
E–150–2016–1–PCT–
01.
PCT/US2017/054863
....................................
October 3, 2017 ........
E–150–2016–1–CN–
02.
201780095506.7 ........
....................................
October 3, 2017 ........
E–150–2016–1–EP–03
17928082.1 ................
....................................
October 3, 2017 ........
E–150–2016–1–JP–04
2020–519137 .............
....................................
October 3, 2017 ........
E–150–2016–1–SG–
05.
112020002882V .........
....................................
October 3, 2017 ........
E–150–2016–1–US–06
10,981,866 .................
April 20, 2021 ............
October 3, 2017 ........
E–150–2016–1–HK–07
62020015610.2 ..........
....................................
October 3, 2017 ........
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and
Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and
Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and
Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives And Their Use As Radiotherapy And
Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives And Their Use As Radiotherapy And
Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives And Their Use As Radiotherapy And
Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives And Their Use As Radiotherapy And
Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives And Their Use As Radiotherapy And
Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives And Their Use As Radiotherapy And
Imaging Agents.
Chemical Conjugates of Evans Blue Derivatives And Their Use As Radiotherapy And
Imaging Agents.
lotter on DSK11XQN23PROD with NOTICES1
NIH Ref No.
The patent rights in these inventions
have been assigned to the Government
of the United States of America. The
prospective patent license may be
granted in a field of use directed to
radiotherapeutics for nasopharyngeal
cancer and the extent of the exclusive
license may be territorially restricted to
the United States, its Territories,
Commonwealths and Possessions; and
Asia.
The invention pertains to a
radiotherapeutics against cancers that
express somatostatin receptor.
Radionuclide therapy directed against
tumors that express somatostatin
receptors (SSTRs) has proven effective
for the treatment of advanced, low- to
intermediate-grade neuroendocrine
tumors. The subject radiotherapeutic
covered by the patent estate includes a
somatostatin (SST) peptide derivative
like octreotate (TATE), conjugated to an
Evans Blue (EB) analog, and further
chelated via DOTA to therapeutic
radionuclide 177Lu, a beta emitter. The
EB analog reversibly binds to circulating
serum albumin and improves the
pharmacokinetics of SST peptide
derivatives and reduce peptide-receptor
radionuclide therapy toxicity. EB analog
conjugated to octreotate (EB–TATE) has
been shown by the inventors to provide
reversible albumin binding in vivo and
extended half-life in circulation. When
EB–TATE is slowly released into the
VerDate Sep<11>2014
17:35 Oct 14, 2022
Jkt 259001
tumor microenvironment, tumor uptake
and internalization into SSTR positive
tumors resulted in delivery of
radioactive particles and tumor cell
killing. EB–TATE displayed
significantly more favorable
pharmacokinetics than TATE alone by
achieving higher tumor to non-tumor
penetration as evidenced by positron
emission tomography.
Complete applications for a license in
the prospective field of use that are
timely filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive patent
license.
Comments and objections submitted
to this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Michael D. Davis,
Deputy Director, National Heart, Lung, and
Blood Institute, Office of Technology Transfer
and Development.
[FR Doc. 2022–22476 Filed 10–14–22; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Clinical Center; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Board of Scientific
Counselors of the NIH Clinical Center.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended for the review, discussion,
and evaluation of individual grant
applications conducted by the Clinical
Center, including consideration of
personnel qualifications and
performance, and the competence of
individual investigators, the disclosure
of which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Board of Scientific
Counselors of the NIH Clinical Center.
Date: November 14, 2022.
Time: 10 a.m. to 5:30 p.m.
Agenda: To review and evaluate to review
and evaluate the Rehabilitation Medicine
Department, presentations, interviews and
reports.
Place: Clinical Center, 10 Center Drive,
Bethesda, MD 20892 (Virtual Meeting).
Date: November 15, 2022.
E:\FR\FM\17OCN1.SGM
17OCN1
]]>Agencies
[Federal Register Volume 87, Number 199 (Monday, October 17, 2022)]
[Notices]
[Pages 62866-62867]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-22476]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent License: Radiotherapeutics
for Nasopharyngeal Cancer
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Heart, Lung and Blood Institute (NHLBI), National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an exclusive patent license to Molecular
Targeting Technologies, Inc. (MTTI); a Delaware corporation, with its
principle place of business in West Chester, Pennsylvania, to practice
the inventions embodied in the issued patents and patent applications
listed in the Supplementary Information section of this notice.
DATES: Only written comments and/or applications for a license which
are received by the NHLBI Office of Technology Transfer and Development
November 1, 2022 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated exclusive patent license
should be directed to: Michael Davis, JD, Ph.D., Deputy Director, NHLBI
OTTAD, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479,
phone number 301-451-9032, or [email protected].
SUPPLEMENTARY INFORMATION: The following and all continuing U.S. and
foreign patents/patent applications thereof are the intellectual
properties to be licensed under the prospective agreement to MTTI:
--------------------------------------------------------------------------------------------------------------------------------------------------------
Patent No. or patent
NIH Ref No. application No. Issue date Filing date Title
--------------------------------------------------------------------------------------------------------------------------------------------------------
E-150-2016-0-US-01................ 62/333,427........... ................................ May 9, 2019..................... Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-0-PCT-02............... PCT/US2017/031696.... ................................ May 9, 2017..................... Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-0-CN-03................ 201780029003X........ ................................ November 9, 2018................ Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-0-EP-04................ 3455206.............. November 4, 2020................ May 9, 2017..................... Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-0-JP-05................ 2018-558662.......... TBD (Allowed)................... May 9, 2017..................... Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-0-US-06................ 10,696,637........... June 30, 2020................... May 9, 2017..................... Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-0-SG-07................ 11201809982R......... November 8, 2021................ May 9, 2017..................... Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-0-CH-08................ 3455206.............. November 4, 2020................ May 9, 2017..................... Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-0-DE-09................ 3455206.............. November 4, 2020................ May 9, 2017..................... Chemical Conjugates of
(Certificate No. Evans Blue Derivatives
602017027023.7). and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-0-FR-10................ 3455206.............. November 4, 2020................ May 9, 2017..................... Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
[[Page 62867]]
E-150-2016-0-GB-11................ 3455206.............. November 4, 2020................ May 9, 2017..................... Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-0-IE-12................ 3455206.............. November 4, 2020................ May 9, 2017..................... Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-0-IT-13................ 3455206.............. November 4, 2020................ May 9, 2017..................... Chemical Conjugates of
Evans Blue Derivatives
and Their Use as
Radiotherapy and Imaging
Agents.
E-150-2016-1-PCT-01............... PCT/US2017/054863.... ................................ October 3, 2017................. Chemical Conjugates of
Evans Blue Derivatives
And Their Use As
Radiotherapy And Imaging
Agents.
E-150-2016-1-CN-02................ 201780095506.7....... ................................ October 3, 2017................. Chemical Conjugates of
Evans Blue Derivatives
And Their Use As
Radiotherapy And Imaging
Agents.
E-150-2016-1-EP-03................ 17928082.1........... ................................ October 3, 2017................. Chemical Conjugates of
Evans Blue Derivatives
And Their Use As
Radiotherapy And Imaging
Agents.
E-150-2016-1-JP-04................ 2020-519137.......... ................................ October 3, 2017................. Chemical Conjugates of
Evans Blue Derivatives
And Their Use As
Radiotherapy And Imaging
Agents.
E-150-2016-1-SG-05................ 112020002882V........ ................................ October 3, 2017................. Chemical Conjugates of
Evans Blue Derivatives
And Their Use As
Radiotherapy And Imaging
Agents.
E-150-2016-1-US-06................ 10,981,866........... April 20, 2021.................. October 3, 2017................. Chemical Conjugates of
Evans Blue Derivatives
And Their Use As
Radiotherapy And Imaging
Agents.
E-150-2016-1-HK-07................ 62020015610.2........ ................................ October 3, 2017................. Chemical Conjugates of
Evans Blue Derivatives
And Their Use As
Radiotherapy And Imaging
Agents.
--------------------------------------------------------------------------------------------------------------------------------------------------------
The patent rights in these inventions have been assigned to the
Government of the United States of America. The prospective patent
license may be granted in a field of use directed to radiotherapeutics
for nasopharyngeal cancer and the extent of the exclusive license may
be territorially restricted to the United States, its Territories,
Commonwealths and Possessions; and Asia.
The invention pertains to a radiotherapeutics against cancers that
express somatostatin receptor. Radionuclide therapy directed against
tumors that express somatostatin receptors (SSTRs) has proven effective
for the treatment of advanced, low- to intermediate-grade
neuroendocrine tumors. The subject radiotherapeutic covered by the
patent estate includes a somatostatin (SST) peptide derivative like
octreotate (TATE), conjugated to an Evans Blue (EB) analog, and further
chelated via DOTA to therapeutic radionuclide \177\Lu, a beta emitter.
The EB analog reversibly binds to circulating serum albumin and
improves the pharmacokinetics of SST peptide derivatives and reduce
peptide-receptor radionuclide therapy toxicity. EB analog conjugated to
octreotate (EB-TATE) has been shown by the inventors to provide
reversible albumin binding in vivo and extended half-life in
circulation. When EB-TATE is slowly released into the tumor
microenvironment, tumor uptake and internalization into SSTR positive
tumors resulted in delivery of radioactive particles and tumor cell
killing. EB-TATE displayed significantly more favorable
pharmacokinetics than TATE alone by achieving higher tumor to non-tumor
penetration as evidenced by positron emission tomography.
Complete applications for a license in the prospective field of use
that are timely filed in response to this notice will be treated as
objections to the grant of the contemplated exclusive patent license.
Comments and objections submitted to this notice will not be made
available for public inspection and, to the extent permitted by law,
will not be released under the Freedom of Information Act, 5 U.S.C.
552.
Michael D. Davis,
Deputy Director, National Heart, Lung, and Blood Institute, Office of
Technology Transfer and Development.
[FR Doc. 2022-22476 Filed 10-14-22; 8:45 am]
BILLING CODE 4140-01-P
